Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - capsules - azithromycin as dihydrate 250 mg - azithromycin - azithromycin - infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 30.7 mg - capsule, hard - excipient ingredients: gelatin; propylene glycol; dimethicone 12500; brilliant blue fcf aluminium lake; titanium dioxide; shellac; strong ammonia solution - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 122.9 mg - capsule, hard - excipient ingredients: titanium dioxide; shellac; gelatin; dimethicone 12500; propylene glycol; brilliant blue fcf aluminium lake; strong ammonia solution - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - dabigatran etexilate mesilate 126.83 mg eqv dabigatran etexilate - capsule - 110 mg - dabigatran etexilate mesilate 126.83 mg eqv dabigatran etexilate 110 mg

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - dabigatran etexilate mesilate 86.48mg eqv dabigatran etexilate - capsule - 75 mg - dabigatran etexilate mesilate 86.48mg eqv dabigatran etexilate 75 mg

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - dabigatran etexilate mesilate 172.95mg eqv dabigatran etexilate - capsule - 150.00mg - dabigatran etexilate mesilate 172.95mg eqv dabigatran etexilate 150.00mg

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - mefenamic acid, quantity: 250 mg - capsule, hard - excipient ingredients: lactose monohydrate; titanium dioxide; purified water; quinoline yellow; gelatin; sodium lauryl sulfate; brilliant scarlet 4r - treatment of primary dysmenorrhoea and primary menorrhagia.,short-term relief of mild to moderate pain such as dental pain and soft tissue pain.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - dabigatran etexilate mesilate - capsule - 75mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - dabigatran etexilate mesilate - capsule - 110mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - dabigatran etexilate mesilate - capsule - 150mg